title: Failed efficacy of soluble human CD83-Ig in allogeneic mixed lymphocyte reactions and experimental autoimmune encephalomyelitis: implications for a lack of therapeutic potential.
abstract: Soluble forms of CD83, a dendritic cell-specific surface glycoprotein, have been strongly proposed to be of therapeutic utility in inflammatory conditions such as multiple sclerosis and transplantation. We demonstrate here, however, that eukaryotically expressed, recombinant soluble human CD83-Ig molecules fail to achieve efficacy in model systems for those conditions: mouse experimental autoimmune encephalomyelitis models in vivo or in mixed lymphocyte reactions in vitro. These results raise concern as to the viability of a eukaryotically expressed soluble CD83 strategy for clinical therapeutic use.
authors: Roche Palo Alto, LLC, Palo Alto, CA 94304, USA.
authors: Achal
authors: A
authors: Pashine
authors: Ulrich
authors: U
authors: Göpfert
authors: Jinzhi
authors: J
authors: Chen
authors: Eike
authors: E
authors: Hoffmann
authors: Paul S
authors: PS
authors: Dietrich
authors: Stanford L
authors: SL
authors: Peng
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000097:blood / Q000276:immunology* / Q000627:therapeutic use*; D003713:Dendritic Cells / Q000276:immunology; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007136:Immunoglobulins / Q000097:blood / Q000276:immunology* / Q000627:therapeutic use*; D007959:Lymphocyte Culture Test, Mixed; D008562:Membrane Glycoproteins / Q000097:blood / Q000276:immunology* / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000627:therapeutic use; D000097802:CD83 Antigen
chemical_list: D015703:Antigens, CD; D007136:Immunoglobulins; D008562:Membrane Glycoproteins; D011993:Recombinant Fusion Proteins; D000097802:CD83 Antigen